Iovance Biotherapeutics reported a 13% increase in quarterly revenue to approximately $68 million, with a gross margin of 43% due to improved execution. Lifileucel showed promising results in advanced non-small cell lung cancer with no median duration of response after 25+ months. The company plans to centralize manufacturing in 2026 to reduce costs and improve margins.

The company’s Amtagvi U.S. launch has seen strong commercial execution across treatment networks, with over 80 authorized treatment centers activated. Growth is expected as more centers open, driving demand with improved referral trends among medical oncologists. Manufacturing turnaround time has improved to an average of 32 days, enhancing accessibility for patients.

Expansion of Amtagvi globally is underway, with approvals anticipated in the UK, Australia, and Switzerland. Health Canada granted the first approval outside the U.S. for advanced melanoma patients. Iovance is finalizing a strategy with the European Medicines Agency to support EU marketing authorization for Amtagvi.

Pipeline progress includes positive interim data for lifileucel in advanced non-small cell lung cancer, showing an objective response rate of 26% and no median duration of response after 25+ months. The company plans to complete enrollment in 2026 and support a Biologics License Application. Other programs for melanoma and solid tumors are also advancing.

Iovance Biotherapeutics aims to lead in TIL therapies for cancer patients, with a focus on harnessing the immune system to target and destroy cancer cells. Amtagvi is the first FDA-approved T cell therapy for solid tumors. The company is committed to continuous innovation in cell therapy to improve patient outcomes.

Read more at GlobeNewswire: Iovance Biotherapeutics Highlights Business Achievements,